首页 / 产品 / 蛋白 / 细胞因子、趋化因子与生长因子
| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | MIP3a |
| Uniprot No | P78556 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 27-96aa |
| 氨基酸序列 | ASNFDCCLGY TDRILHPKFI VGFTRQLANE GCDINAIIFH TKKKLSVCAN PKQTWVKYIV RLLSKKVKNM |
| 预测分子量 | 8.0 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于MIP3α(CCL20)重组蛋白研究的模拟参考文献示例(非真实文献，仅供格式参考)：
1. **《Expression and functional characterization of recombinant human CCL20 in Escherichia coli》**
- 作者：Zhang L, et al.
- 摘要：研究利用大肠杆菌系统高效表达重组人CCL20蛋白，通过His标签纯化获得高纯度产物，并验证其通过CCR6受体激活下游信号通路的生物活性。
2. **《MIP-3α enhances dendritic cell migration and antigen presentation in chronic inflammation》**
- 作者：Smith J, et al.
- 摘要：通过哺乳动物细胞表达重组MIP-3α，发现其可显著促进树突状细胞趋化，并在慢性炎症模型中增强抗原呈递能力，提示其免疫治疗潜力。
3. **《Structural analysis of CCL20 and its interaction with HIV-1 envelope protein》**
- 作者：Kim S, et al.
- 摘要：解析重组CCL20的晶体结构，揭示其与HIV-1包膜蛋白gp120的结合位点，为基于CCL20的抗病毒药物开发提供依据。
4. **《Recombinant MIP-3α as a mucosal vaccine adjuvant in murine models》**
- 作者：Wang Y, et al.
- 摘要：评估CHO细胞表达的重组MIP-3α作为黏膜疫苗佐剂的效果，结果显示其能显著增强抗原特异性IgA抗体反应及Th17细胞应答。
注：以上为模拟内容，实际文献需通过PubMed/Google Scholar等平台检索关键词(如"CCL20 recombinant protein"或"MIP-3α expression")。
MIP-3α (Macrophage Inflammatory Protein-3α), also known as CCL20 (C-C motif chemokine ligand 20), is a small cytokine belonging to the CC chemokine family. It plays a critical role in immune regulation, particularly in recruiting lymphocytes and dendritic cells to inflammatory sites. Discovered in the late 1990s, MIP-3α is encoded by the CCL20 gene in humans and is structurally characterized by four conserved cysteine residues, with the first two adjacent (CC motif). It binds exclusively to the chemokine receptor CCR6. a G-protein-coupled receptor expressed on immune cells like immature dendritic cells, memory T cells, and B cells.
Biologically, MIP-3α is produced by epithelial cells, macrophages, and dendritic cells in response to pro-inflammatory stimuli such as TNF-α, IL-1β, or microbial pathogens. It orchestrates immune surveillance by directing CCR6-expressing cells to mucosal surfaces, lymphoid tissues, and sites of infection or injury. This chemokine is pivotal in bridging innate and adaptive immunity, facilitating pathogen clearance, and maintaining tissue homeostasis. Dysregulation of MIP-3α/CCR6 signaling is implicated in chronic inflammatory diseases (e.g., rheumatoid arthritis, psoriasis), autoimmune disorders, and cancer progression.
Recombinant MIP-3α proteins are engineered using expression systems like *E. coli* or mammalian cells, ensuring high purity and bioactivity. These proteins retain the native structure and function, enabling research applications such as *in vitro* leukocyte migration assays, immune cell differentiation studies, and therapeutic exploration. As a research tool, recombinant MIP-3α aids in dissecting chemokine-receptor interactions, inflammatory pathways, and potential drug targets. Its clinical relevance extends to vaccine development and immunotherapy strategies aimed at modulating immune cell trafficking.
×
